These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 27039129)

  • 1. Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial.
    Pang PS; Teerlink JR; Voors AA; Ponikowski P; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Kriger J; Prescott MF; Hua TA; Severin T; Metra M
    JACC Heart Fail; 2016 Jul; 4(7):591-599. PubMed ID: 27039129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
    Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
    Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
    J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
    Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
    Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.
    Cotter G; Voors AA; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Milo O; Hua TA; Qian M; Severin TM; Teerlink JR; Metra M; Davison BA
    Eur J Heart Fail; 2015 Nov; 17(11):1133-43. PubMed ID: 26333529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study.
    Felker GM; Mentz RJ; Teerlink JR; Voors AA; Pang PS; Ponikowski P; Greenberg BH; Filippatos G; Davison BA; Cotter G; Prescott MF; Hua TA; Lopez-Pintado S; Severin T; Metra M
    Eur J Heart Fail; 2015 Dec; 17(12):1262-70. PubMed ID: 26333655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
    Pang PS; Teerlink JR; Boer-Martins L; Gimpelewicz C; Davison BA; Wang Y; Voors AA; Severin T; Ponikowski P; Hua TA; Greenberg BH; Filippatos G; Felker GM; Cotter G; Metra M
    Am Heart J; 2017 May; 187():62-69. PubMed ID: 28454809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Serelaxin in Patients with Acute Heart Failure.
    Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C;
    N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
    Demissei BG; Cotter G; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Severin TM; Wang Y; Qian M; Teerlink JR; Metra M; Davison BA; Voors AA
    Eur J Heart Fail; 2017 Aug; 19(8):1001-1010. PubMed ID: 28133908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality.
    Davison BA; Metra M; Senger S; Edwards C; Milo O; Bloomfield DM; Cleland JG; Dittrich HC; Givertz MM; O'Connor CM; Massie BM; Ponikowski P; Teerlink JR; Voors AA; Cotter G
    Eur J Heart Fail; 2016 Aug; 18(8):1041-50. PubMed ID: 27114058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial).
    Pang PS; Fermann GJ; Hunter BR; Levy PD; Lane KA; Li X; Cole M; Collins SP
    Circ Heart Fail; 2019 Jul; 12(7):e005931. PubMed ID: 31288565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P
    Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
    Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
    J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
    Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-sensitivity troponin T improves the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: results from the LURIC Study.
    Ivandic BT; Spanuth E; Kleber M; Grammer TB; März W
    Clin Chem Lab Med; 2011 Jun; 49(6):1053-8. PubMed ID: 21574877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
    Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
    J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.
    Pascual-Figal DA; Manzano-Fernández S; Boronat M; Casas T; Garrido IP; Bonaque JC; Pastor-Perez F; Valdés M; Januzzi JL
    Eur J Heart Fail; 2011 Jul; 13(7):718-25. PubMed ID: 21551163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
    Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
    Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study.
    Bosselmann H; Egstrup M; Rossing K; Gustafsson I; Gustafsson F; Tonder N; Kistorp CN; Goetze JP; Schou M
    Int J Cardiol; 2013 Dec; 170(2):202-7. PubMed ID: 24182673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.